• ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspective
Weekly Newscast
dvm360 LIVE!™
Insights
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Client Handouts
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Coverage
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2022 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Virbac announces the launch of TULISSIN Injectable Solution in the US

December 14, 2021
Bob Alaburda, Senior Editor

Virbac will market TULISSIN cattle products directly and its swine products through a partnership with Pharmgate.

Virbac is slated to launch its first product in the US food production animal market after receiving FDA approval of TULISSIN (Tulathromycin injectable) Injectable Solution for use in cattle and swine.

According to the release, TULISSIN 100 Injectable Solution offers a concentration of 100 mg/mL and will be available in 50-, 100-, 250-, and 500-mL bottles. TULISSIN 25 Injectable Solution offers a concentration of 25 mg/mL and will come in 100- and 250-mL bottles.1 Virbac will market the cattle products with its own direct sales force.

In addition, the swine products will be marketed through an agreement with Pharmgate.

"We are excited to collaborate with a reputable animal health organization, such as Virbac, as they launch a range of products into the US large animal market," says Ed Seed, head of Global Sales & Marketing for Pharmgate, in the release.

"Adding this initial product, TULISSIN, to our portfolio over the coming year will expand our offering in fulfilling our customers' complete therapeutic product needs," continued Seed.

Virbac currently has a major presence in the large animal health segment in several regions, including Asia, Pacific, Europe, and Latin America. What's more, this product will be Virbac’s first to entry into this segment of the US market.

"We see the market authorization of TULISSIN as a major accomplishment and are excited about our introduction into the food-producing animal market for the US. I am convinced that Pharmgate, with its broad portfolio of products and strong field team, key relationships, and expertise, is a perfect fit for Virbac to successfully enter the swine segment," said Francois Fournier, president & CEO, Virbac North America.

Reference

  1. Virbac announces the approval of TULISSIN® (Tulathromycin injectable) in the US and a collaboration with Pharmgate. PR Newswire. Accessed November 13, 2021. https://www.prnewswire.com/news-releases/virbac-announces-the-approval-of-tulissin-tulathromycin-injectable-in-the-us-and-a-collaboration-with-pharmgate-301439539.html

Related Content:

Food AnimalsMedicalBusinessAssociates
Dr. Marty Pets announces new designs for its products
Dr. Marty Pets announces new designs for its products
Completing a neurological exam is like following a cooking recipe
Completing a neurological exam is like following a cooking recipe
3 Must-reads on veterinary rehabilitation
3 Must-reads on veterinary rehabilitation

Latest News

Pet Acoustics opens contest submissions for singing canines

Dr. Marty Pets announces new designs for its products

Brookfield Zoo welcomes South American tapir calf

Veterinary medicine in the military with Zachary Tooley

View More Latest News